Mayne Pharma Acquires FDA-approved halobetasol foam, Complementing US Dermatology Portfolio

Mayne Pharma Group Limited ("Mayne Pharma") (ASX: MYX) has acquired the FDA approved halobetasol propionate foam 0.05% for an investment of up to US$32 million and an ongoing earn out payment Halobetasol foam is a highly complementary dermatol... Biopharmaceuticals, Acquisition, Dermatology Mayne Pharma, halobetasol foam, psoriasis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news